)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Septerna
Septerna (SEPN) investor relations material
Septerna 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Platform and portfolio overview
Focused on GPCR drug discovery using the Native Complex Platform, enabling rapid identification and optimization of compounds for difficult-to-drug targets.
Portfolio includes programs with early clinical readouts, targeting validated biological and clinical needs.
Well-capitalized with cash runway into at least 2029, following an IPO and a Novo collaboration.
Therapeutic focus spans endocrinology, immunology, inflammation, and metabolic diseases, but remains area-agnostic.
Platform enables discovery of novel binding pockets and rapid structure-based design, solving over 150 GPCR structures to date.
Lead programs and clinical progress
SEP-479, a PTH receptor agonist for hypoparathyroidism, is entering phase I trials in the first half of 2025, with IND-enabling studies completed and strong preclinical data.
SEP-479 demonstrated normalization of serum calcium and phosphate in animal models and favorable PK/PD in monkeys.
SEP-631, a negative allosteric modulator of MRGPRX2 for mast cell diseases, is completing phase I, with data to be presented at AAAAI in March.
SEP-631 shows potent, insurmountable inhibition of MRGPRX2, with broad potential across dermatological and non-dermatological indications.
TSHR program targets Graves' disease and thyroid eye disease with a negative allosteric modulator, showing reversal of disease in animal models and nearing candidate selection.
Market opportunities and strategy
Hypoparathyroidism market estimated at 70,000–80,000 US patients, with unmet need for oral therapies due to drawbacks of current injectable and calcium-based treatments.
SEP-479 aims to address both naive and switch patients, offering a convenient oral option with broad applicability.
SEP-631's mechanism is differentiated by its insurmountable receptor inhibition and slow off-rate, with CSU as the initial indication and plans to explore additional mast cell-driven diseases.
TSHR program aspires to provide a universal, disease-modifying therapy for both Graves' and thyroid eye disease, overcoming limitations of current treatments.
Novo Nordisk collaboration covers multiple incretin and metabolic targets, with Novo funding all R&D and offering milestone and royalty payments.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Septerna earnings date
Q4 202527 Mar, 2026
Septerna
Next Septerna earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Septerna Inc. is a biotechnology company focused on the discovery and development of innovative therapies targeting G protein-coupled receptors (GPCRs). The company leverages proprietary technology to design small molecule therapeutics aimed at addressing unmet medical needs across various disease areas. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage